MedTrace Logo

A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)

NCT07082868 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2026-05-06

No results posted yet for this study

Summary

The purpose of this study is to find out whether the combination of epcoritamab and ibrutinib is a safe treatment approach that causes few or mild side effects in people with relapsed/refractory primary central nervous system lymphoma (PCNSL) or secondary central nervous system lymphoma (SCNSL).

Conditions

  • Primary Central Nervous System Lymphoma (PCNSL)
  • Primary Central Nervous System Lymphoma
  • Relapsed Primary Central Nervous System Lymphoma
  • Refractory Primary Central Nervous System Lymphoma
  • Central Nervous System Lymphoma
  • Secondary Central Nervous System Lymphoma
  • Secondary Central Nervous System Lymphoma (SCNSL)

Interventions

DRUG

Epcoritamab

Epcoritamab will be administered at the study site clinic, as a SC injection

DRUG

ibrutinib

Ibrutinib should be self-administered daily by the participant and should be taken at approximately the same time each day

Sponsors & Collaborators

Principal Investigators

  • Christian Grommes, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-08-13
Primary Completion
2028-08-31
Completion
2028-08-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07082868 on ClinicalTrials.gov